BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20730598)

  • 1. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
    Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.
    Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ
    Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
    Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
    J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
    Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
    Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
    Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
    Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells.
    Luqmani YA; Al Azmi A; Al Bader M; Abraham G; El Zawahri M
    Int J Oncol; 2009 Jan; 34(1):231-42. PubMed ID: 19082494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer.
    Shahmoradgoli M; Riazalhosseini Y; Haag D; Becker N; Hovestadt V; Heck S; Sinn HP; Schneeweiss A; Mannherz O; Sahin Ö; Lichter P
    Int J Cancer; 2013 Jun; 132(11):2714-9. PubMed ID: 23169272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.
    Chang EC; Frasor J; Komm B; Katzenellenbogen BS
    Endocrinology; 2006 Oct; 147(10):4831-42. PubMed ID: 16809442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation.
    Ito I; Hanyu A; Wayama M; Goto N; Katsuno Y; Kawasaki S; Nakajima Y; Kajiro M; Komatsu Y; Fujimura A; Hirota R; Murayama A; Kimura K; Imamura T; Yanagisawa J
    J Biol Chem; 2010 May; 285(19):14747-55. PubMed ID: 20207742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.
    Ellison-Zelski SJ; Alarid ET
    Mol Cancer; 2010 Sep; 9():263. PubMed ID: 20920219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.